Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04206813 · ClinicalTrials.gov registry record · Phase 4
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
A Phase 4 study of HPV Infection, sponsored by Boston Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 352
- Enrollment target
- 1
- Study location
NCT04206813 is a Phase 4 study of HPV Infection that is active but no longer recruiting, run by Boston Medical Center. The registered enrollment target is 352 participants, above the 209-participant average among 13 other HPV Infection trials with a reported enrollment target (68% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04206813, a Phase 4 study of HPV Infection, is active but no longer recruiting, sponsored by Boston Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 352 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9 among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an antibody response that is not inferior to that observed of a 3-dose schedule of Gardasil 9 among women aged 16-26 years old. The investigators thought that having a 2-dose vaccination regimen for individuals 16 to 45 would provide a more robust dataset than those of 27 to 45 years old.
Conditions Studied
Interventions
- DRUG Gardasil 9 2 dose regimen
- DRUG Gardasil 9 3 dose regimen
- DRUG Gardasil 9 rescue dose
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04206813
The ClinicalTrials.gov registry entry for NCT04206813 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 209-participant average among 13 other HPV Infection trials with a reported enrollment target (68% higher). The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HPV Infection appearing as the primary indexed condition, and to 3 interventions - of which Gardasil 9 2 dose regimen is the first listed.
NCT04206813 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04206813 about?
NCT04206813 is a clinical study titled "An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen". The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9 among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an antibody response that is not inferior to that observed of a 3-dose schedule of Gardasil 9 among women aged 16-26 ye...
What is the current status of trial NCT04206813?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 352 participants. The study started on 2020-12-01. Estimated completion is 2026-06.
What conditions does trial NCT04206813 study?
This clinical trial studies the following conditions: HPV Infection.
What interventions are being tested in trial NCT04206813?
The interventions under investigation include: Gardasil 9 2 dose regimen (DRUG), Gardasil 9 3 dose regimen (DRUG), Gardasil 9 rescue dose (DRUG).
Who is sponsoring clinical trial NCT04206813?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04206813 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Immunogenicity of Fractional Dose of the HPV Vaccines
ACTIVE NOT RECRUITING · Phase 4
-
Intradermal, Fractional Dose of HPV Vaccines:
ACTIVE NOT RECRUITING · Phase 4
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
RECRUITING · NA
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.